pharmaphorum

JULY 18, 2022

It had expected the drug would not face biosimilar competition in Europe until at least 2027. Last year, Polpharma and Sandoz won a patent challenge in Europe that resulted in revocation of a key patent on Tysabri in the EU, slashing Biogen’s protection for the brand by more than five years.

Competition 52

Competition Marketing Sales Medicine 52

pharmaphorum

OCTOBER 1, 2022

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US. Gilenya made revenues of $2.8 Sales in the first half of this year fell 19% to $1.16

Competition 52

Competition Pharma Marketing Sales 52

Medico Reach

DECEMBER 2, 2022

billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. Also pharmaceutical companies approaching Clinical Research Organizations for their R&D activities to stay competitive, flexible, and profitable against all odds. In 2022, the global clinical research market stands at $63.6

Consulting 98

Consulting Medicine Specialization Medical 98

pharmaphorum

OCTOBER 17, 2022

Novartis’ hopes that the Supreme Court would protect its big-selling multiple sclerosis drug Gilenya from generic competition have been dashed. 9,187,405, granted in 2015, which comes to an end in 2027. If they do so, Novartis has predicted it will lose $300 million in sales over the remainder of this year.

Competition 52

Competition Marketing Sales Pharma 52

Contrarian Sales Techniques

FEBRUARY 1, 2023

This is what sets your product apart from the competition and gives your customers a reason to choose your product over others. billion by 2027, growing at a CAGR of 7.7% from 2020 to 2027. Create a unique selling proposition : The article discussed the importance of creating a unique selling proposition (USP) for your product.

Sales Strategy 52

Sales Strategy Sales Sales pitches Prospecting 52

PM360

JULY 13, 2023

Market research and competitive analysis Conduct thorough market research to understand the existing solutions and identify your competition. MarketsandMarkets, “Polyols Market by Type, Application, End-use Industry, and Region – Global Forecast to 2027,” December 2022. References: 1.

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

LEVO Health

JULY 15, 2024

billion by 2027. To stand out in this competitive landscape, businesses must focus on patient engagement, comprehensive service offerings, strong marketing and branding, and strategic partnerships with top-tier telehealth service providers like WellSync and medical marketing experts like Levo Health.

Marketing 52

Marketing Side effects Education Medical 52

PM360

MAY 21, 2024

By 2027, it’s expected to have about 90% of market penetration—that is over 300 million OTT users. In today’s intensely competitive market, not leveraging the benefits of CTV is a lost opportunity. slevas@optimizerx.com STACEY LEVAS SVP, Demand Generation & Marketing Communications Optimizer U.S.

Media 105

Media Healthcare Healthcare Marketing 105

Clarivate

JULY 16, 2019

Customer experience has been growing rapidly in the last few years because it is one of the most significant ways to differentiate your brand in this increasingly competitive market. 97% of executives believe that improving CX is very important to achieving or maintaining a competitive advantage.

Competition 40

Competition Sales Leads Marketing 40

pharmaphorum

JANUARY 27, 2023

There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.” Bates continued: “We expected a fall in investment following two bumper years, but it should still be considered a warning.

Pharma 52

Pharma Manufacturing Medicine Biopharma 52

Clarivate

AUGUST 27, 2024

With the global atrial fibrillation market at $6 billion today, that rate of growth would push it to $12 billion by mid-2027, if not sooner, with PFA accounting for about 70% of the market. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up.

Marketing 52

Marketing FDA Competition Medical 52

Pharmaceutical Technology

NOVEMBER 30, 2022

Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

Medical 98

Medical Manufacturing Insurance Side effects 98

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Sales Leads 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

FEBRUARY 7, 2023

However, a delicate balance will need to be struck between the need for affordable and accessible medicinal products and the desire to foster innovation and competitiveness in the EU. of the MDR and Article 110.4 of the IVDR for medical devices and in vitro diagnostic medical devices (IVDs).

Medical 117

Medical Government Marketing Medicine 117

Pharmaceutical Technology

FEBRUARY 6, 2023

A Pliant spokesperson said, “This successful transaction, along with existing cash, cash equivalents, loan agreement and short-term investments, provides for operations to be funded to mid-2027, a year past the expected IPF Phase 2b clinical trial readout.” The company said a Phase IIb trial initiation should be expected in mid-2023.

Marketing 59

Marketing Pharmaceutical FDA Prospecting 59

Clarivate

APRIL 24, 2023

After Walgreens upped its ownership stake in the primary-care company VillageMD from 30 to 63 percent and then announced plans to operate 1,000 clinics by 2027, the writing was on the wall: to stay competitive and manage costs in CVS’ newly integrated Aetna plan, CVS could benefit by making a larger bid for primary care of its own.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Pharmaceutical Technology

JUNE 21, 2023

Analysts forecast the biologics market to be worth $120 billion more than small molecules by 2027. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

Leads 52

Leads Prospecting Pharmaceutical Marketing 52

Pharmaceutical Technology

APRIL 24, 2023

GlobalData predicts that Comirnaty’s sales will increase by more than 20% between 2024 and 2027. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

Pharmaceutical 59

Pharmaceutical Medicine FDA Sales 59

Evolve Your Success

OCTOBER 31, 2023

It’s very competitive. By 2027, they are projected to be about $10 billion. Medical sale is a lot more volatile. Straight out the gate, probably about four years ago, I interviewed with the company for a full-fledged sales rep within the pacemaker world. I made it all the way to my very last interview. He had experience.

Engineering 130

Engineering Sales Medical sales Medical 130

Spotio

JULY 5, 2023

billion by 2027—a 48% jump from where the industry was last year, in 2022. Your value proposition should be something like, “We offer customers the peace of mind they crave at a lower price point than the competition.” The home security market is booming. According to recent research , the industry is expected to hit $84.4

Sales 40

Sales Prospecting Sales pitches Leads 40

Impetus Digital

MARCH 15, 2024

In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. However, with rapid growth comes growing pains.

Recruitment 78

Recruitment Patients Healthcare Provider Healthcare 78

Pharmaceutical Technology

NOVEMBER 4, 2022

of gross domestic product (GDP) in R&D by 2027. UK’s competitive potential. The plan says investment in science and research in life sciences must be maintained and grown over the next decade, with an aim of investing 2.4%

Pharma 93

Pharma Government Pharmaceutical Medicine 93

Medico Reach

FEBRUARY 8, 2023

billion by 2027. Global personalized medicine market forecast for the year 2027: Source The leading pharma firms are designing revolutionary, custom-made treatment methods. Now is the time for various B2B businesses targeting the pharma industry to buckle up, get competitive and align their strategies for propensity.

Pharma 52

Pharma Medicine Marketing Prospecting 52

pharmaphorum

JANUARY 16, 2023

Rapid growth is forecasted from 2023 onwards: some industry observers predict that the global POC and rapid Dx market projected to reach $75bn by 2027, up from $45bn in 2022, at a CAGR of 10.7%. Innovation will power the market. To thrive, pharma must ask increasingly tough questions about the viability of candidates for clinical development.

FDA 98

FDA Healthcare Healthcare Medicine 98

Clarivate

AUGUST 20, 2024

In 2025, CMS will select another 15 Part D drugs for negotiations that will take effect in 2027. In highly competitive categories like diabetes, net price could be half of the list price. Although the initial set of drugs included for negotiations was limited to ten, the scope of this program will expand over time.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52